medRxiv
July 10, 2022
M. Madsen, Anja Sofie Petersen, Dea Siggaard Stenbæk et al.
5 citations
preprint
Abstract Chronic cluster headache (CCH) is an excruciating disorder of unknown pathophysiology, but hypothalamic dysfunction has been implicated. CCH is difficult to treat but on a case-basis, the psychedelic compound psilocybin is said to have beneficial effects. In this first-ever clinical trial ( NCT04280055 ), we evaluate in a small open-label study of CCH patients the feasibility and...
Frontiers in Psychiatry
July 7, 2022
Maggie Kiraga, Kim P. C. Kuypers, Malin V. Uthaug et al.
24 citations
Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmacological and cognitive-behavioral therapy result in deficient treatment responses. Historical and recent research suggests psychedelic drugs may be efficacious in alleviating anxiety-related symptoms among healthy and clinical populations. The main...
Scientific Reports
June 30, 2022
Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow et al.
53 citations
Abstract Psilocybin microdosing involves repeated self-administration of mushrooms containing psilocybin at doses small enough to not impact regular functioning. Microdose practices are diverse and include combining psilocybin with substances such as lion’s mane mushrooms (Hericium erinaceus; HE) and niacin (vitamin-B3). Public uptake of microdosing has outpaced evidence, mandating further...
Brain and Neurological Disorders
June 21, 2022
Abdul Wahab Alahmari
Many psychedelics drugs are praised on social media platforms like YouTube by non-experts or bias documentaries claiming that these drugs have therapeutic effects on addicted patients or clarity of the mind. The aim of this paper is to collect a neuroimaging documentation of these psychedelics’ drugs and their effect on the brain. That can be documented on MRI, CT, or any other imaging modalities.
Fortschritte der Neurologie · Psychiatrie
June 20, 2022
Christopher W. Schmidt, Max Wolff, Gerhard Gründer et al.
5 citations
Zusammenfassung Ziel der Studie In den letzten Jahren konnten Studien, in denen die Verwendung von Psilocybin zur Behandlung psychischer Störungen untersucht wurde, vielversprechende Ergebnisse zeigen. Vor diesem Hintergrund wurden Einstellungen von ausgebildeten Psychiater*innen und Psychotherapeut*innen zu Psilocybin und Psilocybin-unterstützten Therapien untersucht. Methodik Eine...
Journal of Personalized Medicine
June 19, 2022
Vojtěch Viktorin, Inga Griškova-bulanova, Aleksandras Voicikas et al.
19 citations
Psilocybin is a classical serotoninergic psychedelic that induces cognitive disruptions similar to psychosis. Gamma activity is affected in psychosis and is tightly related to cognitive processing. The 40 Hz auditory steady-state responses (ASSR) are frequently used as indicators to test the ability to generate gamma activity. Based on previous literature, we studied the impact of psilocybin on...
International Journal of Molecular Sciences
June 16, 2022
Adam Wojtas, Agnieszka Bysiek, Agnieszka Wawrzczak-Bargieła et al.
110 citations
Clinical studies provide evidence that ketamine and psilocybin could be used as fast-acting antidepressants, though their mechanisms and toxicity are still not fully understood. To address this issue, we have examined the effect of a single administration of ketamine and psilocybin on the extracellular levels of neurotransmitters in the rat frontal cortex and reticular nucleus of the thalamus...
Scientific Reports
June 15, 2022
Meghan Hibicke, Charles D. Nichols
25 citations
Abstract Psilocybin has been shown to be a powerful, long-lasting antidepressant in human clinical trials and in rodent models. Although rodents have commonly been used to model psychiatric disorders, Drosophila have neurotransmitter systems similar to mammals and many comparable brain structures involved in similar behaviors. The forced swim test (FST), which has been used extensively to...
Neuroscience & Biobehavioral Reviews
June 6, 2022
Corinna L. Felsch, Kim P. C. Kuypers
23 citations
BACKGROUND: Current first-line treatment for social anxiety disorder (SAD), one of the most prevalent anxiety disorders, is limited in its efficacy. Hence, novel treatment approaches are urgently needed. The current review suggests a combination of meditation-based interventions and the administration of a psychedelic as a future alternative treatment approach. While both separate treatments...
SURG Journal
June 1, 2022
Anthony Principe
1 citation
This review presents a general background of psilocybin pharmacology and discusses its uses in treating various mental health disorders such as depression, anxiety, obsessive-compulsive disorder, and addiction. A summary of preliminary clinical trials utilizing psilocybin in each disorder is presented, along with an analysis of the neurobiological mechanisms that could explain the results. The...